Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Sanbin Wang
A real-world, multi-center, retrospective study of autologous hematopoietic stem cell transplantation in 33 patients with HIV-associated lymphoma in China (CALL-006 Study)
To the Editor: Since 2017, the incidence of HIV-associated non-Hodgkin lymphoma (NHL) has exceeded that of Kaposi sarcoma (KS), becoming the most common HIV-defined malignancy [1]. The advent of antiretroviral therapy (ART), along with improvements in supportive care for hematologic malignancies, has enabled HIV-associated lymphoma to tolerate more intensive treatment regimens.
A multi-center clinical trial of allogeneic hematopoietic stem cell transplantation in transfusion-dependent thalassemia - Nature Communications
|
Abstract Allogeneic stem cell transplantation (allo-HSCT) has recently been approved as standard therapy for transfusion-dependent thalassemia (TDT) but remains limited to the use of HLA-matched sibling donors (MSDs), due to a lack of large-scale prospective studies evaluating the use of grafts from alternative donors. Here, we report the results of a non-randomised, interventional, phase 4 clinical trial evaluating allo-HSCT from alternative donors for the treatment of TDT.
By Rongrong Liu, Hongwen Xiao, Chunjie Qin, Jiong Hu, Jianming Luo, Hong Chang Chen, Xi Zhang, Xiaolin Yin, Guanye Nai, Guyun Wang, Zan Li, Wei Tang, Hua Zhang, Xiaotao Wang, Mei Lan, Chuande Liao, Tonghua Yang, Sanbin Wang, Jinxiong Huang, Yunyan He, Li Wang, Zhongming Zhang, Lianjin Liu, Zhenbin Wei, Lingling Shi, Meiqing Wu, Qi Zhou, Borje S. Andersson, Xiaojun Huang, Yongrong Lai
|
Nature
Verified
Incidence and risk factors for graft failure after allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis - Bone Marrow Transplantation
Abstract Graft failure (GF) is a barrier to successful allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with myelofibrosis (MF). We investigated the incidence, risk factors, and prognosis for GF after allo-HSCT for MF. Two hundred and eleven patients with MF who underwent allo-HSCT across 32 hematology centers in China between December 2008 and December 2024 were retrospectively analyzed.
Efficacy and Safety of Hetrombopag Versus Thrombopoietin in Promoting Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Multicenter, Randomized Controlled Clinical Trial
Conflicts of Interest The authors declare no conflicts of interest. Supporting Information Filename Description ajh27746-sup-0001-Supinfo.docxWord 2007 document , 669.1 KB Data S1. Supporting Information. References 1, , , et al., “Hematopoietic Stem Cell Transplantation Activity in China 2019: A Report From the Chinese Blood and Marrow Transplantation Registry Group,” Bone Marrow Transplantation 56 (2021): 2940–2947.
Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma
Background T lymphoblastic lymphoma (T-LBL) is an aggressive non-Hodgkin’s lymphoma (NHL) of rare lymphoblastoid origin in the T-cell lineage. It most commonly occurs in children and young adults; predominantly in males; and often involves the mediastinum, bone marrow, and central nervous system. T-LBL progresses rapidly, converting to acute lymphoblastic leukemia (ALL) in a short time, and has a poor prognosis, with a 5-year survival rate of <20%.
Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma
Chengcheng Zhang1†, Linling Wang2†, Qianzhen Zhang2, Junjie Shen2, Xia Huang2, Meiling Wang2, Yi Huang2, Jun Chen2, Yanmin Xu2, Wenxu Zhao2, Yanan Qi2, Yunyan Li2, Yanjiao Ou1, Zhi Yang2* and Cheng Qian2* 1Department of Hepatobiliary Surgery, Southwest Hospital, Army Medical University, Chongqing, China 2Chongqing Key Laboratory of Gene and Cell Therapy, Institute of Precision Medicine and Biotechnology, Chongqing Precision Biotech Co. Ltd., Chongqing, China Introduction: Chimeric antigen...
Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial | Journal of Clinical Oncology
The prognosis of patients with high-risk (HR) acute myeloid leukemia (AML) continues to worsen after treatment. One potentially curative regimen for HR-AML is allogeneic hematopoietic stem-cell transplantation (allo-HSCT).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Sanbin
Contact Sanbin, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack